Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor

Abstract

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

Description

technical field

[0001] The invention relates to berberine and doxorubicin, in particular to the application of a mixed preparation of berberine and doxorubicin in the preparation of anti-doxorubicin-induced cardiac dysfunction or anti-tumor drugs. Background technique

[0002] Doxorubicin is an anti-tumor drug widely used clinically. It has very significant curative effects on leukemia, lymphoma, breast cancer, lung cancer, etc., and is currently one of the most commonly used anti-tumor drugs in clinical practice. The main side effect of doxorubicin is myocardial toxicity, which can not only cause arrhythmia, but also induce progressive cardiomyopathy and congestive heart failure with the accumulation of doses. Since the 1980s, many new advances have been made in the research on the molecular mechanism of adriamycin cardiotoxicity. At present, most studies believe that it is possible that adriamycin can activate endogenous cardiomyopathy through oxidative stress pathways or ...

Images